Roche Pharmaceutical Development and Sales Overview
Ophthalmology franchise: Excellent Vabysmo launch
More than 165k vials shipped in the US in the first 7 months
CHFM
200
150
100
50
Q122
Q2 22
■ US
Europe
International ■Japan
Q3 22
Q3 update
Vabysmo
VABYSMO
SuSvim o™
ranibizumab injection Form
100mm
Roche
• US: Strong uptake with switches primarily from aflibercept and first
naïve patient starts
US: Permanent J-code granted on October 1st
• EU: Approval granted in DME and nAMD
•
Ph III (TENAYA/LUCERNE) 2 year data in nAMD presented at ASRS
• Real-world study (TRUCKEE*) update presented at AAO supporting
efficacy and safety profile
Susvimo
• Voluntary recall due to manufacturing issue
Outlook 2022
Ph III (BALATON/COMINO) results for Vabysmo in RVO expected
⚫ Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR expected
⚫ Ph III (MEERKAT/SANDCAT) IL-6 mAb in UME to be initiated
*Investigator initiated study; DME=diabetic macular edema; nAMD-neovascular age-related macular degeneration; RVO-retinal vein occlusion; DR-diabetic retinopathy; UME=uveitic macular edema;
mAb-monoclonal antibody; Eylea (aflibercept) is a registered trademark/product of Regeneron
28View entire presentation